Ibandronic acid














































































































Ibandronic acid
Ibandronate.svg
Clinical data

AHFS/Drugs.com
 International Drug Names
License data



  • EU EMA: by INN


  • US FDA: ibandronate_sodium
Pregnancy
category


  • US: C (Risk not ruled out)


Routes of
administration		 Oral, intravenous
ATC code

  • M05BA06 (WHO)
Legal status
Legal status

  • In general: ℞ (Prescription only)

Pharmacokinetic data
Bioavailability 0.6%
Protein binding 90.9 to 99.5%
(concentration-dependent)
Metabolism Nil
Elimination half-life
 10 to 60 hours
Excretion Renal
Identifiers
CAS Number

  • 114084-78-5 ☑Y

PubChem CID
  • 60852
IUPHAR/BPS
  • 3059
DrugBank

  • DB00710 ☒N
ChemSpider

  • 54839 ☑Y
UNII
  • UMD7G2653W
KEGG

  • D08056 ☑Y
ChEMBL

  • ChEMBL997 ☑Y
ECHA InfoCard
100.214.537 Edit this at Wikidata
Chemical and physical data
Formula
C9H23NO7P2
Molar mass 319.229 g/mol
3D model (JSmol)
  • Interactive image

.mw-parser-output .nobold{font-weight:normal}
 ☒N☑Y (what is this?)
  (verify)

Ibandronic acid (INN) or ibandronate sodium (USAN) is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer.[1] It may also be used to treat hypercalcemia (elevated blood calcium levels).




Contents






  • 1 Medical uses


  • 2 Adverse effects


  • 3 Brand names


  • 4 References


  • 5 External links





Medical uses


Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women.[2] In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.


Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.[3]



Adverse effects


In 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint or muscle pain.[4] A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur.
[5] The drug also has been associated with osteonecrosis of the jaw, relatively rare but serious condition.[6]



Brand names


Ibandronic acid is marketed under the trade names Boniva in the USA, Bondronat in Europe, Bonviva in Asia, Ibandrix in Ecuador, Adronil in Pakistan, Bondrova in Bangladesh and Bonprove in Egypt.



References





  1. ^ Bauss F, Schimmer RC (March 2006). "Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis". Therapeutics and clinical risk management. 2 (1): 3–18. PMC 1661644. PMID 18360577..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ "boniva". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.


  3. ^ Sittig HB (2012). "Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate". Onkologie. 35 (6): 380–7. doi:10.1159/000338947. PMID 22722461.


  4. ^ "Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)". U.S. Food and Drug Administration. Retrieved 27 October 2010.


  5. ^ "Drugs Commonly Prescribed for Osteoporosis Patients are Effective at Reducing Risk of Hip and Spine Fractures, But Panel Says May be Related to Unusual Thigh Bone Fractures When Used Long Term". Journal of Bone and Mineral Research=27 October 2010.


  6. ^ "Osteonecrosis of the jaw (ONJ) and drug treatments for osteoporosis" (PDF). nos.org.uk. The National Osteoporosis Society.




External links




  • Ibandronate bound to proteins in the PDB


  • Boniva Osteoporosis Treatment by GlaxoSmithKline and Roche Laboratories

  • Boniva adverse events reported to the FDA










Comments

Post a Comment

Popular posts from this blog

Information security

Image
This article is part of a series on Information security Related security categories Internet security Cyberwarfare Computer security Mobile security Network security Threats Computer crime Vulnerability Eavesdropping Malware Spyware Ransomware Trojans Viruses Worms Rootkits Bootkits Keyloggers Screen scrapers Exploits Backdoors Logic bombs Payloads Denial of service Defenses Computer access control Application security Antivirus software Secure coding Secure by default Secure by design Secure operating systems Authentication Multi-factor authentication Authorization Data-centric security Encryption Firewall Intrusion detection system Mobile secure gateway Runtime application self-protection (RASP) v t e Information security , sometimes shortened to InfoSec , is the practice of preventing unauthorized access, use, disclosure, disruption, modification, inspection, recording or destruction of information. Th...
Read more

Volkswagen Group MQB platform

Image
The Volkswagen Group MQB platform is the company's strategy for shared modular design construction of its transverse, front-engine, front-wheel-drive layout (optional front-engine, four-wheel-drive layout) automobiles. Volkswagen spent roughly $60bn [1] developing this new platform and the cars employing it. The platform underpins a wide range of cars from the supermini class to the mid size SUV class. MQB allows Volkswagen to assemble any of its cars based on this platform across all of its MQB ready factories. This allows the Volkswagen group flexibility to shift production as needed between its different factories. Beginning in 2012, Volkswagen Group marketed the strategy under the code name MQB , which stands for Modularer Querbaukasten , translating from German to "Modular Transversal Toolkit" or "Modular Transverse Matrix". [2] [3] MQB is one strategy within VW's overall MB (Modularer Baukasten or modular matrix) program which also includes th...
Read more

刘萌萌

Image
body.skin-minerva .mw-parser-output table.infobox caption{text-align:center} 刘萌萌 女演员 罗马拼音 Liu Meng Meng 英文名 Cya 国籍   中国 民族 汉族 出生 ( 1989-10-16 ) 1989年10月16日 （ 29歲）   中国辽宁省大连市 职业 演员、艺人 语言 汉语 教育程度 沈阳音乐学院 北京电影学院表演系进修班 活跃年代 2011年至今 唱片公司 浙江永乐影视制作有限公司 经纪公司 浙江永乐影视制作有限公司 网站 刘萌萌 官方微博 刘萌萌 （1989年10月16日 － ），汉族，中国演员，2010年参加湖南卫视《芒果训练营》而出道至今，凭借电视剧《爱情公寓》“诺澜”一角走红。北京电影学院10级表演系（进修班）毕业。 目录 1 主要经历 2 影视作品 2.1 电视剧 2.2 电影 2.3 综艺节目 3 参考文献 4 外部链接 主要经历 1989年，出生于辽宁省大连市一个工人家庭； 2006年，考入沈阳音乐学院舞蹈系本科班学习； 2010年，参加湖南卫视《芒果训练营》演艺新秀比赛而出道 [1] ；進入北京电影学院表演系进修班 2011年，出演电视剧《隋唐演义》“琼花公主”一角色； 2012年，担任电视剧《爱情公寓》“诺澜”一角并开始走红 [2] ； 2013年，担任电视剧《利箭纵横》《利剑行动》 [3] 女主角“林筱雨” 2014年，参加江苏卫视真人秀栏目《花样年华》 [4] 备受瞩目 [5] 。 影视作品 电视剧 首播年份 剧名 角色 备注 2012 《爱情公寓3》 诺澜 2012 《利箭行动》 林筱雨 2013 《隋唐演义》 琼花公主 2013 《决战燕子门》 马晓婉 2014 《利箭纵横》 林筱雨 2014 《屌丝日记》 林洛霏 網絡劇 2014 《爱情公寓4》 诺澜 ...
Read more